MASS vaccination is the most cost-effective way of dealing with seasonal and pandemic influenza, according to the Fluresp consortium. This should be followed by targeted treatment of those displaying symptoms, rather than the mass prescription of antiviral drugs, it says. The Fluresp project is the world's first extensive cost-effectiveness analysis of responses to flu, the consortium says. It brought together experts in flu, public health, health economics and computer sciences from 10 European countries.
展开▼
